ADC Therapeutics SA General and Administrative Expenses | ADCT

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses ADC Therapeutics SA

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
36.6 M	41.9 M	48.4 M	74.4 M	71.5 M	55.1 M	13.8 M	8.6 M	7.81 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
74.4 M	7.81 M	39.8 M

Quarterly General and Administrative Expenses ADC Therapeutics SA

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
8.82 M	9.9 M	-	8.33 M	8.82 M	9.96 M	-	10 M	10.2 M	12 M	-	9.36 M	11.4 M	15.1 M	-	-	-	19 M	-	16.6 M	19.4 M	17.6 M	-	14.2 M	15 M	5.88 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
19.4 M	5.88 M	12.3 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	24.1 M	-	-	-	Russia
AbbVie ABBV	14 B	$ 257.12	0.86 %	$ 455 B	USA
AbCellera Biologics ABCL	83.2 M	$ 10.89	4.11 %	$ 3.25 B	Canada
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	92 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	29.9 M	-	-14.46 %	$ 27.9 M	USA
ASLAN Pharmaceuticals Limited ASLN	13.2 M	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Adaptimmune Therapeutics plc ADAP	87.3 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Abeona Therapeutics ABEO	65 M	$ 5.42	0.18 %	$ 287 M	USA
iTeos Therapeutics ITOS	49.1 M	-	-	$ 411 M	USA
Galmed Pharmaceuticals Ltd. GLMD	3.64 M	$ 4.63	21.05 %	$ 20 M	Israel
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
BioXcel Therapeutics BTAI	20.5 M	$ 0.07	9.81 %	$ 855 K	USA
Allakos ALLK	38.8 M	-	-	$ 28.6 M	USA
Cyclerion Therapeutics CYCN	2.48 M	$ 23.52	458.67 %	$ 98.9 M	USA
Lexicon Pharmaceuticals LXRX	37.3 M	$ 2.0	0.3 %	$ 726 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	22.2 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	15.9 M	$ 5.12	0.1 %	$ 981 M	Canada
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
NextCure NXTC	12.7 M	$ 7.0	0.55 %	$ 19.9 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Nanobiotix S.A. NBTX	20.4 M	$ 37.01	0.27 %	$ 1.77 T	France
ACADIA Pharmaceuticals ACAD	549 M	$ 27.83	0.32 %	$ 4.69 B	USA
Axcella Health AXLA	15.8 M	-	-16.42 %	$ 249 M	USA
SQZ Biotechnologies Company SQZ	26.3 M	-	57.95 %	$ 12.8 M	USA
Atreca BCEL	31.5 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
Achieve Life Sciences ACHV	16.3 M	$ 7.06	0.41 %	$ 308 M	USA
Baudax Bio BXRX	14.7 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	13.5 M	-	-10.95 %	$ 876 K	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
Codiak BioSciences CDAK	27.6 M	-	-55.98 %	$ 2.15 M	USA
ChemoCentryx CCXI	78.9 M	-	-	$ 3.74 B	USA
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
AC Immune SA ACIU	16.1 M	$ 2.76	2.6 %	$ 278 M	Schweiz
Cerevel Therapeutics Holdings CERE	113 M	-	-	$ 7.29 B	USA
Aclaris Therapeutics ACRS	22 M	$ 5.32	1.27 %	$ 652 M	USA
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Adagene ADAG	7.08 M	$ 3.4	2.72 %	$ 201 M	China
Adial Pharmaceuticals ADIL	5.18 M	$ 4.9	0.08 %	$ 3.28 M	USA
ADMA Biologics ADMA	91.6 M	$ 9.23	0.16 %	$ 2.2 B	USA
Adaptive Biotechnologies Corporation ADPT	72.7 M	$ 24.2	0.08 %	$ 3.67 B	USA
Agenus AGEN	54.4 M	$ 6.94	0.73 %	$ 206 M	USA
Agios Pharmaceuticals AGIO	180 M	$ 33.6	0.16 %	$ 1.95 B	USA